Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. - Wikidata - awgldk - TriplyDB

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

http://www.wikidata.org/entity/Q33306317

about

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen Cancer pharmacogenomics: strategies and challenges Applications of CYP450 testing in the clinical setting Clinical use of pharmacogenomic tests in 2009 Germline pharmacogenomics in oncology: decoding the patient for targeting therapy Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen Precision medicine: from pharmacogenomics to pharmacoproteomics The effects of a novel hormonal breast cancer therapy, endoxifen, on the mouse skeleton PharmGKB: understanding the effects of individual genetic variants A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese German Recommendations for Diagnosis and Treatment of Breast Cancer 2008. What is New from the Breast Commission of the German Gynaecological Oncology Working Group (AGO)?CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study The Impact of CYP2D6 Genotyping on Tamoxifen Treatment Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17 A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.PharmGKB summary: tamoxifen pathway, pharmacokinetics Coprescription of tamoxifen and medications that inhibit CYP2D6.Expectations, validity, and reality in pharmacogenetics.Genotype-guided tamoxifen therapy: time to pause for reflection?Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma Orally administered endoxifen is a new therapeutic agent for breast cancer.Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics.Breast Cancer Systemic Therapy: The Need for More Economically Sustainable Scientific Strategies in the World.Pharmacogenomics: a systems approach.Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects.CYP2D6 genotype and tamoxifen: considerations for proper nonprospective studies.Tamoxifen and CYP2D6: a contradiction of data.The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer Effects of CYP induction by rifampicin on tamoxifen exposure.Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

P2860

Q21195205-779B5678-CC9C-419E-8C50-13A9DB25B71E Q24289309-EEF836FE-3CED-40C3-839A-6F245D9B9B14 Q24621760-2CAF0529-F086-48B2-AD32-5B5FCF22F719 Q24657536-E001E9A2-55B7-4022-8827-070AAA18EA1B Q27022557-C5A62CEF-4230-4BF4-A52A-2D0B1356742C Q27026180-DCE1E7D7-E069-48EC-AE47-B113BCA130A1 Q28076871-F31581FE-95B9-4A00-A431-3098AD416371 Q28539057-E641B2CB-4D0C-4C00-86C8-52319BD93CA2 Q28754550-941E435E-A13F-49A6-A3BE-074D932D0490 Q28943542-F045010F-47C4-48BE-9656-8AFA8996CFF6 Q30319696-41F8DBF9-A2D7-473F-88C1-ED9DB3080B76 Q30400967-1D9A951A-57FD-46C4-80C0-7B3F5E09D74B Q30416074-ACEDA2F3-AE69-4D15-801D-5A80C7A115FA Q33368192-1F13D924-F4D1-41B0-8531-07F200B033CD Q33611502-621D1890-7E4A-47ED-B12B-84D2B86FB6BB Q33634928-75523A4D-676B-413C-BD10-5D61413D95C0 Q33664433-B4737B83-0A77-43DD-BE76-668571FC97AB Q33692784-3DF68471-9974-47E1-B9C8-E78FD49091E3 Q33739494-8E3B075A-E4DE-4FEA-8993-AEFF9866DFB2 Q33781027-3338D345-A7E4-4ED5-A298-6281F35930BF Q33828149-D3453D1E-1501-4EBB-AB89-460C09487CCB Q33855494-BCB6AF05-B52E-4D64-9606-4E504B148A39 Q33898184-E11168F3-D401-4CE1-8114-E3DE3982E15D Q33926313-4ED715A0-0356-4F51-9435-696945C66793 Q33955759-6BACA277-10E4-4E93-882D-F7BB80DB6701 Q33965328-357AD3EF-F9EE-453E-9FC1-C08260AC18F4 Q34091195-3A123FB6-1E79-4699-8A6D-6F20D10A5128 Q34095909-BB5296B2-E1BC-4070-8F65-FFF29DE84BB7 Q34095952-4DBB65A6-DADC-49F7-B1E4-CD5669917694 Q34095977-69F82389-B79D-4E78-9A0B-97F5D049E76D Q34137575-9D2DF181-CFEA-4CEE-8EB7-4551422203C5 Q34146176-111248CB-6B9C-4BF9-A9A2-BAC22A080631 Q34205830-CDFF7CC8-BCC2-4AEA-A4F7-3200C7EA7764 Q34244463-475DF1CA-1FC5-434B-B982-DD7292C86978 Q34253646-B7FDFCB8-8D82-4B2C-B458-08AAC7E0DD8D Q34278391-6753D623-2DB6-47E3-920D-24551D783945 Q34307589-2139FE5F-2A11-4436-9684-D64DFF0BEE09 Q34315833-26918C95-60E4-4D6F-A8E6-E28A720FB99A Q34346501-B4D9DF00-558E-4724-B8A2-5F1448548B81 Q34677193-20AD45D4-E2AE-4ECB-8AE3-52C6F5100419

P2860

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

http://www.wikidata.org/entity/Q33306317

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@ast

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@en

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@nl

type

label

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@ast

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@en

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@nl

prefLabel

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@ast

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@en

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@nl

P1433

Q33306317-09AE39F4-B3E0-4AF6-AED3-EC92D1A7DDA2

P1476

Q33306317-415033D3-7364-4AF4-8F7F-9C6FA3B677D1

P2093

Q33306317-36627553-FC1F-48E0-8A8F-2314D2831666

Q33306317-486F3BB9-2D13-405E-A714-546A512ED12D

Q33306317-55E739C8-3E5F-4BFD-9D68-FCEE6CF38BBC

Q33306317-5DF554B7-F1F6-4672-A018-A07CD1F48434

Q33306317-B34B4FE2-D23E-409F-ADAF-F184DCEEE2DF

Q33306317-D3E2C5CD-B03E-439B-98DB-44D460109887

Q33306317-DE0E94BD-54FE-4B23-910C-506A63001CED

P304

Q33306317-B68E0C3C-C0C0-41C8-8722-599C3A55C517

P31

Q33306317-FDF9D6B8-ABBD-4EB6-9211-47C20D03F03A

P356

Q33306317-366956BE-829A-4DCE-8FF8-D60268AD025C

P407

Q33306317-CE9D8243-E8B4-450F-938D-CF3BFE01D198

P433

Q33306317-DB7D1EC4-6DF5-4A5B-81D0-1B098C9B94D6

P478

Q33306317-E511BCE5-DB9C-4D3F-9099-79079C483C41

P50

Q33306317-55C56505-6582-4B5E-A6ED-DF4D1796E0CB

Q33306317-EC944669-537F-4745-9D8D-723168AF61A7

P577

Q33306317-E6314E8F-1134-450F-9AF0-FA491841C333

P5875

Q33306317-9C3274D5-C53F-4CA7-A00F-B6B2FCE3401C

P698

Q33306317-DE5C5748-C3B0-4118-9F4A-B83D48203C5C

P921

Q33306317-704AA1DA-4B37-4BED-BF85-B20CE6A2F21B

P356

JCO.2007.12.2705

P1433

Journal of Clinical Oncology

P1476

Breast cancer treatment outcom ...... CYP2D6 and CYP2C19 genotypes.

@en

P2093

Lydia Antoniadou

http://www.w3.org/2001/XMLSchema#string

Matthias Schwab

http://www.w3.org/2001/XMLSchema#string

Michel Eichelbaum

http://www.w3.org/2001/XMLSchema#string

Peter Fritz

http://www.w3.org/2001/XMLSchema#string

Thomas Muerdter

http://www.w3.org/2001/XMLSchema#string

Werner Schroth

http://www.w3.org/2001/XMLSchema#string

Wolfgang Simon

http://www.w3.org/2001/XMLSchema#string

P304

5187-5193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2007.12.2705

http://www.w3.org/2001/XMLSchema#string

P407

P433

33

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Ulrich M. Zanger

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5822091

http://www.w3.org/2001/XMLSchema#string

P698

18024866

http://www.w3.org/2001/XMLSchema#string

P921